Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs

Signage for Novartis AG at a building in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.  Bloomberg | Bloomberg | Getty Images Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results. The stock pared gains … Read more

Biotech IPOs heated up, but haven’t fully recovered

Angelp | Istock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! After a two-year dry spell, initial public offerings by biotech companies showed signs of life during the first three months of 2024.  But it’s too early to say that … Read more

Weight loss drug patients spend less on restaurants, takeout: survey

A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, … Read more

U.S. drug shortages reach record high, hitting Wegovy

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.  Hollie Adams | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Drug shortages in the U.S. are at a record high, leaving countless patients … Read more

Eli Lilly weight loss drug Zepbound effective in sleep apnea trials

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan McDermid | Reuters Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. The … Read more

Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says 

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan McDermid | Reuters Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according … Read more

Johnson & Johnson (JNJ) earnings Q1 2024

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street’s expectations as sales in its medical devices business surged. Meanwhile, the company’s total revenue for the … Read more

Eli Lilly’s top drug last year is softening. But it may not matter for the stock

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. But that might not be enough to stop its stock from climbing higher. Prescription data for multiple Eli Lilly drugs — especially type-2 diabetes treatment Trulicity — points to weaker trends in … Read more

Weight loss, diabetes drugs not linked to suicidal thoughts: EU probe

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.  Hollie Adams | Reuters European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator … Read more

Moderna halts Kenya vaccine plant plans as Covid shot demand plunges

A nurse prepares a dose of Moderna Covid-19 vaccine at Oltepesi Dispensary in Kajiado, Kenya, on September 9, 2021. Patrick Meinhardt | AFP | Getty Images Moderna on Thursday said it has paused plans to build a vaccine-manufacturing site in Kenya after a steep drop in demand for its Covid vaccines. The biotech company said … Read more